Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study-Reference-Cited by-同舟云学术

Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study

Published:2021-05-05 Issue:5 Volume:193 Page:906-914
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Abu Sabaa Amal¹²^ORCID,Mörth Charlott²³,Hasselblom Sverker⁴,Hedström Gustaf²,Flogegård Max⁵,Stern Mimmi⁶,Andersson Per‐Ola⁶^ORCID,Glimelius Ingrid²^ORCID,Enblad Gunilla²

Affiliation:

1. Centre for Research and Development Uppsala University/Region Gavleborg Sweden

2. Department of Immunology, Genetics and Pathology Experimental and Clinical Oncology Uppsala University Sweden

3. Centre for Clinical Research Sormland Uppsala University UppsalaSweden

4. Department of Research, Development and Education Region Halland HalmstadSweden

5. Department of Internal Medicine Falun General Hospital FalunSweden

6. Department of Hematology South Alvsborg HospitalBoras and Sahlgrenska AcademyGothenburg University Gothenburg Sweden

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17206

Reference29 articles.

1. The 2016 updated WHO classification of lymphoid neoplasias

2. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

3. Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study

4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

5. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study;European Journal of Haematology;2024-07-22

2. Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma;Discover Oncology;2024-04-05

3. Лечение диффузной В-крупноклеточной лимфомы в условиях ГКБ № 52 Департамента здравоохранения Москвы: ретроспективное клиническое исследование, отражающее опыт одного центра, на основе анализа данных из собственного локального регистра;Clinical Oncohematology;2024-02-20

4. Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma;Cancer Medicine;2023-12-22

5. Demographic characteristics and prognosis of HHV8-positive diffuse large B-cell lymphoma, not otherwise specified: Insights from a population-based study with a 10-year follow-up;Medicine;2023-12-15